Aigen Investment Management LP Cuts Stock Position in Doximity, Inc. (NASDAQ:DOCS)

Aigen Investment Management LP lowered its stake in Doximity, Inc. (NASDAQ:DOCS) by 24.0% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 14,800 shares of the company’s stock after selling 4,677 shares during the period. Aigen Investment Management LP’s holdings in Doximity were worth $790,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. M&T Bank Corp grew its stake in shares of Doximity by 6.7% in the 4th quarter. M&T Bank Corp now owns 8,601 shares of the company’s stock worth $459,000 after buying an additional 543 shares during the last quarter. Atria Investments Inc grew its stake in shares of Doximity by 6.4% in the 4th quarter. Atria Investments Inc now owns 8,975 shares of the company’s stock worth $479,000 after buying an additional 539 shares during the last quarter. Assetmark Inc. lifted its position in Doximity by 31,906.1% in the 4th quarter. Assetmark Inc. now owns 10,562 shares of the company’s stock valued at $564,000 after acquiring an additional 10,529 shares in the last quarter. Victory Capital Management Inc. lifted its position in Doximity by 3.0% in the 4th quarter. Victory Capital Management Inc. now owns 34,516 shares of the company’s stock valued at $1,843,000 after acquiring an additional 1,016 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Doximity by 3.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 778,524 shares of the company’s stock valued at $41,565,000 after acquiring an additional 25,523 shares in the last quarter. Hedge funds and other institutional investors own 87.19% of the company’s stock.

Insider Transactions at Doximity

In other news, Director Timothy S. Cabral sold 20,000 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $57.62, for a total value of $1,152,400.00. Following the completion of the sale, the director now directly owns 6,360 shares in the company, valued at $366,463.20. This represents a 75.87 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 37.40% of the stock is currently owned by company insiders.

Doximity Price Performance

NASDAQ:DOCS opened at $65.86 on Friday. The firm has a market capitalization of $12.29 billion, a price-to-earnings ratio of 65.86, a price-to-earnings-growth ratio of 4.10 and a beta of 1.34. Doximity, Inc. has a one year low of $22.96 and a one year high of $85.21. The business has a fifty day moving average price of $62.68 and a 200-day moving average price of $51.41.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on DOCS shares. Raymond James reaffirmed an “outperform” rating and issued a $83.00 price objective (up from $65.00) on shares of Doximity in a research report on Friday, February 7th. KeyCorp lowered their price objective on Doximity from $70.00 to $65.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Stephens started coverage on Doximity in a research report on Friday, December 20th. They issued an “equal weight” rating and a $55.00 price objective on the stock. Leerink Partners raised Doximity from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $60.00 to $90.00 in a research report on Friday, February 7th. Finally, Canaccord Genuity Group cut Doximity from a “buy” rating to a “hold” rating and upped their price objective for the company from $40.00 to $60.00 in a research report on Wednesday, November 13th. Eleven research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $64.22.

Doximity Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.